ReviewFrontiers in genetics2026
Advances in genetics and multi-omics for ischemic stroke: from pathogenesis to clinical translation.
Review in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke is a multifactorial, heterogeneous cerebrovascular disease characterized by high incidence, mortality, disability, and recurrence rates. Currently, computed tomography or magnetic resonance imaging represents the gold standard for diagnosis and guidance of thrombolysis or thrombectomy. However, it has limitations such as the inability to provide rapid detection, distinguish etiologies, perform risk stratification, or enable dynamic monitoring. Therefore, rapid, convenient, and highly sensitive biomarkers hold significant clinical value. In recent years, rapid advancements in genetics and multi-omics technologies have not only driven the discovery of ischemic stroke biomarkers and the elucidation of pathophysiological mechanisms but also demonstrated broad application prospects in clinical translation-covering etiological subtyping, individual risk stratification and screening of high-risk populations, drug target identification, recurrence prediction, and prognostic assessment. These advances have laid a molecular foundation for achieving precise diagnosis and personalized treatment of ischemic stroke. This review summarizes biomarkers for ischemic stroke identified through genome-wide association study and multi-omics technologies. We also discuss the implications of these findings for the biological mechanisms of ischemic stroke and their clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.